Blinatumomab Triggers Rapid T-Cell Shifts and B-Cell Depletion in Acute Leukemia
A scientific review outlines how blinatumomab reshapes T-cell populations, depletes B cells, and encounters multifactorial resistance mechanisms in B-cell acute ...
A scientific review outlines how blinatumomab reshapes T-cell populations, depletes B cells, and encounters multifactorial resistance mechanisms in B-cell acute ...
A 24-year-old man with ankylosing spondylitis achieved sustained kidney remission after receiving rituximab for steroid-refractory IgA vasculitis nephritis with severe ...
A collaborative expert review highlights that extending anti-CD20 infusion intervals in stable multiple sclerosis patients may preserve neuroinflammatory disease control ...
A novel copper-64-labeled monoclonal antibody immunoPET tracer successfully tracked human CD19-positive B cells in the central nervous system of a ...
A retrospective cohort study found ocrelizumab induced predictable, class-specific immunoglobulin declines in multiple sclerosis patients without increasing short-to-mid-term clinically relevant ...
Long-term off-label anti-CD20 therapy effectively manages persistent, benign lymphoproliferative bowel disease in a patient with an activation-induced cytidine deaminase deficiency.
A systematic literature review covering 16,729 patients across 43 studies reveals that cladribine tablets maintain stable immunoglobulin levels and low ...
A patient with severe relapsed and refractory lupus nephritis achieved durable clinical and renal remission following treatment with allogeneic CD19-targeted ...
A review in Clinical and Experimental Medicine outlines how rituximab can lead to prolonged secondary immunodeficiency and evaluates monitoring strategies ...
A retrospective study in Mexico found that 42.9% of patients treated with rituximab developed secondary hypogammaglobulinemia, highlighting the need for ...
A multicenter Italian cohort study of 424 adults with relapsing multiple sclerosis found that ofatumumab achieved consistent clinical and radiological ...
A Japanese case series reports that three men with follicular lymphoma treated with anti-CD20 antibodies improved after ensitrelvir when remdesivir ...
A new comparative review finds that the type II anti-CD20 antibody obinutuzumab succeeded in Phase 3 lupus trials where rituximab ...
A case report details how rituximab controlled severe PR3-ANCA pulmonary-renal syndrome in a dialysis-dependent patient after conventional induction therapy failed.
A cross-sectional study shows that ocrelizumab selectively contracts EBV-specific CD4 T-cell immunity in multiple sclerosis while preserving antiviral defenses against ...
A retrospective real-world study from Milan's San Raffaele institute compares ocrelizumab and ofatumumab as successor therapies for multiple sclerosis patients ...
A two-year real-world study found that ofatumumab sustained B-cell depletion in multiple sclerosis patients while producing significant increases in broad ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.